<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>05562nam a2200889 a 4500</leader>
  <controlfield tag="001">vtls000079397</controlfield>
  <controlfield tag="003">MTX</controlfield>
  <controlfield tag="006">m    eo  d        </controlfield>
  <controlfield tag="007">cr cn |||m|||a</controlfield>
  <controlfield tag="008">160715s2012    nyua   foab   000 0 eng d</controlfield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="a">9781606504086 (electronic bk.)</subfield>
  </datafield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="a">9781606504222 (electronic bk.)</subfield>
  </datafield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="z">9780791860038 (print)</subfield>
  </datafield>
  <datafield tag="020" ind1=" " ind2=" ">
    <subfield code="z">0791860035 (print)</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(OCoLC)811139143</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(CaPaEBR)10605115</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
    <subfield code="a">(CaBNvSL)swl00401402</subfield>
  </datafield>
  <datafield tag="037" ind1=" " ind2=" ">
    <subfield code="a">860038</subfield>
    <subfield code="b">ASME</subfield>
  </datafield>
  <datafield tag="039" ind1=" " ind2="9">
    <subfield code="a">201607151144</subfield>
    <subfield code="b">staff</subfield>
    <subfield code="y">201605041227</subfield>
    <subfield code="z">admin</subfield>
  </datafield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">CaBNVSL</subfield>
    <subfield code="c">CaBNVSL</subfield>
    <subfield code="d">CaBNVSL</subfield>
  </datafield>
  <datafield tag="050" ind1=" " ind2="4">
    <subfield code="a">R857.N34</subfield>
    <subfield code="b">N253 2012</subfield>
  </datafield>
  <datafield tag="060" ind1=" " ind2="4">
    <subfield code="a">QT 36.5</subfield>
    <subfield code="b">N253 2012</subfield>
  </datafield>
  <datafield tag="082" ind1="0" ind2="4">
    <subfield code="a">610.284</subfield>
    <subfield code="2">23</subfield>
  </datafield>
  <datafield tag="099" ind1=" " ind2=" ">
    <subfield code="a">Ebook</subfield>
  </datafield>
  <datafield tag="245" ind1="0" ind2="0">
    <subfield code="a">Nanoparticles and brain tumor treatment</subfield>
    <subfield code="h">[electronic resource] /</subfield>
    <subfield code="c">Gerardo Caruso ... [et al.].</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="a">New York, N.Y. :</subfield>
    <subfield code="b">ASME ;</subfield>
    <subfield code="a">[New York, N.Y.] (222 East 46th Street, New York, NY 10017) :</subfield>
    <subfield code="b">Momentum Press,</subfield>
    <subfield code="c">2012.</subfield>
  </datafield>
  <datafield tag="300" ind1=" " ind2=" ">
    <subfield code="a">1 electronic text (viii, 99 p.) :</subfield>
    <subfield code="b">ill., digital file.</subfield>
  </datafield>
  <datafield tag="490" ind1="1" ind2=" ">
    <subfield code="a">Biomedical and nanomedical technologies</subfield>
  </datafield>
  <datafield tag="504" ind1=" " ind2=" ">
    <subfield code="a">Includes bibliographical references (p. [81]-99).</subfield>
  </datafield>
  <datafield tag="505" ind1="0" ind2=" ">
    <subfield code="a">1. Introduction --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">2. Glioma biology -- 2.1 Invasion and angiogenesis --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">3. Blood-brain barrier -- 3.1 Blood-brain barrier physiology -- 3.2 Blood-brain barrier transport systems --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">4. Nanomedicine and nanotechnology -- 4.1 Nanoparticle drug delivery -- 4.1.1 Nanoparticle distribution -- 4.1.2 Nanoparticle functionalization -- 4.1.3 Nanoparticle targeting -- 4.2 Nanomedicine and cancer -- 4.3 Nanomedicine and toxicity --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">5. Nanoparticle technologies -- 5.1 Polymeric and polymer-drug conjugate nanoparticles -- 5.2 Micelle nanoparticles -- 5.3 Liposomes -- 5.4 Gold and silver nanoparticles -- 5.5 Metal oxide -- 5.6 Magnetic nanoparticles -- 5.7 Carbon nanotubes -- 5.8 Fullerenes -- 5.9 Peptides nanoparticles -- 5.10 Silica nanoparticles -- 5.11 Quantum dots -- 5.12 Dendrimers --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">6. Nanomedicine applications in brain tumors -- 6.1 Brain tumor drug targeting -- 6.1.1 Systemic approaches -- 6.1.2 Physiological approaches -- 6.1.2.1 Receptor-mediated transcytosis -- 6.1.2.2 Adsorptive-mediated transcytosis -- 6.1.2.3 Efflux pump inhibition -- 6.1.2.4 Cell-mediated drug transport -- 6.1.3 Direct CNS approaches -- 6.1.3.1 Intracerebral routes -- 6.1.4 Drug modifications and prodrugs --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">7. Experimental studies --</subfield>
  </datafield>
  <datafield tag="505" ind1="8" ind2=" ">
    <subfield code="a">8. Conclusions -- References.</subfield>
  </datafield>
  <datafield tag="506" ind1=" " ind2=" ">
    <subfield code="a">Restricted to libraries which purchase an unrestricted PDF download via an IP.</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
    <subfield code="a">Despite progresses in surgery, radiotherapy, and in chemotherapy, an effective curative treatment of gliomas does not yet exist. Mortality is still close to 100% and the average survival of patients with GBM is less than 1 year. The efficacy of current anti-cancer strategies in brain tumors is limited by the lack of specific therapies against malignant cells. Besides, the delivery of the drugs to brain tumors is limited by the presence of the blood brain barrier. The oncogenesis of gliomas is characterized by several biological processes and genetic alterations, involved in the neoplastic transformation. The modulation of gene expression to more levels, such as DNA, mRNA, proteins and transduction signal pathways, may be the most effective modality to down-regulate or silence some specific gene functions. Gliomas are characterized by extensive microvascular proliferation and a higher degree of vasculature. In malignant gliomas targeted therapies efficacy is low. In this complex field, it seems to be very important to improve specific selective drugs delivery systems. Drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB. Nanotechnology could be used both to improve the treatment efficacy and to reduce the adverse side effects.</subfield>
  </datafield>
  <datafield tag="530" ind1=" " ind2=" ">
    <subfield code="a">Also available in print.</subfield>
  </datafield>
  <datafield tag="538" ind1=" " ind2=" ">
    <subfield code="a">Mode of access: World Wide Web.</subfield>
  </datafield>
  <datafield tag="538" ind1=" " ind2=" ">
    <subfield code="a">System requirements: Adobe Acrobat reader.</subfield>
  </datafield>
  <datafield tag="588" ind1=" " ind2=" ">
    <subfield code="a">Title from PDF t.p. (viewed on September 26, 2012).</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
    <subfield code="a">Nanomedicine.</subfield>
    <subfield code="9">115923</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
    <subfield code="a">Nanoparticles.</subfield>
    <subfield code="9">115924</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="0">
    <subfield code="a">Brain</subfield>
    <subfield code="x">Tumors</subfield>
    <subfield code="x">Treatment.</subfield>
    <subfield code="9">115925</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="2">
    <subfield code="a">Nanomedicine.</subfield>
    <subfield code="9">115923</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="2">
    <subfield code="a">Nanoparticles.</subfield>
    <subfield code="9">115924</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2="2">
    <subfield code="a">Brain Neoplasms</subfield>
    <subfield code="x">therapy.</subfield>
    <subfield code="9">115926</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanomedicine</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanotechnology</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanoparticles</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanoparticles in Brain Tumor Treatment</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanoparticle Drug Delivery</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanoparticle Targeting</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Blood-Brain Barrier</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Glioma</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Astrocytoma</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Glioblastoma</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Brain Tumor</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Glioma Treatment</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Brain Tumor Drug Targeting</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Angiogenesis</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Polymeric</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Nanoparticles and Brain Tumors</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Carbon Nanotubes and Brain Tumors</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Fullerenes and Brain Tumors</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Silica Nanoparticles and Brain Tumors</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Micelle Nanoparticles and Brain Tumors</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">Liposome and Brain Tumors</subfield>
  </datafield>
  <datafield tag="700" ind1="1" ind2=" ">
    <subfield code="a">Caruso, Gerardo.</subfield>
    <subfield code="9">115927</subfield>
  </datafield>
  <datafield tag="776" ind1="0" ind2="8">
    <subfield code="i">Print version:</subfield>
    <subfield code="z">0791860035</subfield>
    <subfield code="z">9780791860038</subfield>
  </datafield>
  <datafield tag="830" ind1=" " ind2="0">
    <subfield code="a">Biomedical and nanomedical technologies.</subfield>
    <subfield code="9">115928</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
    <subfield code="u">http://portal.igpublish.com/iglibrary/search/MPB0000052.html</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="c">10</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">75946</subfield>
    <subfield code="d">75946</subfield>
  </datafield>
</record>
